June 2025 in “British Journal of Dermatology” Dupilumab can cause psoriasis in some patients.
October 2024 in “American Journal of Case Reports” Baricitinib improved hair loss and arthritis in a lupus patient.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
May 2022 in “Голова и шея.” Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
5 citations
,
July 2023 in “International Journal of Women’s Dermatology” Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
January 2016 in “대한피부과학회지” Bortezomib chemotherapy can cause temporary skin rashes.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
September 2023 in “Journal of the American Academy of Dermatology”
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
82 citations
,
March 2013 in “PLoS ONE” Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
May 2026 in “SHILAP Revista de lepidopterología” Dupilumab effectively treated severe alopecia areata in a child.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Ixekizumab effectively treated severe psoriasis and hair loss in a patient.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
1 citations
,
January 2008 in “SKINmed Dermatology for the Clinician” Treatment with prednisolone and dapsone stopped new blisters and partially healed previous ones.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
1 citations
,
August 2021 in “Journal of Investigative Dermatology” ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
1 citations
,
June 2023 in “JAAD case reports” Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.